Panpharmacy vaistinė - Company finances
|
EUR
|
2021
From: 2021-10-21
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | 23,135 | 116,871 | 173,381 | 215,150 |
| Profit before tax | -767 | -84,590 | -74,578 | -84,702 | -69,631 |
| Net profit | -767 | -84,590 | -74,578 | -84,702 | -69,631 |
| Equity | 39,233 | -45,357 | -119,935 | -204,637 | -274,267 |
| Liabilities | 767 | 131,718 | 219,621 | 275,911 | 335,099 |
| Non-current assets | 0 | 56,360 | 49,058 | 37,776 | 31,141 |
| Current assets | 40,000 | 29,779 | 50,436 | 33,103 | 29,416 |
| Total assets | 40,000 | 86,139 | 99,494 | 70,879 | 60,557 |
|
Taxes paid
|
|||||
| STI taxes | - | - | - | 12,072 | 12,061 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | +405.2% | +48.4% | +24.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -1.9% | -98.2% | -75.0% | -119.5% | -115.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -2.0% | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -365.6% | -63.8% | -48.9% | -32.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | -365.6% | -63.8% | -48.9% | -32.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 9,573 | 56,099 | 86,691 | 107,575 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Panpharmacy vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-07-18 | 2022-07-28 | 0.01 |
| 2022-06-16 | 2022-06-29 | 0.01 |
Panpharmacy vaistinė - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Panpharmacy vaistine, UAB (code 305921132) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €215.2K, up 24.1% year on year and 84.1% over two years, showing steady top-line expansion. However, profitability remained negative: net profit for 2025 was -€69.6K, although the loss was narrower than in 2024 (-€84.7K) and 2023 (-€74.6K). The profit margin improved from -63.8% in 2023 to -48.9% in 2024 and -32.4% in 2025, indicating better operating efficiency despite continued losses. The balance sheet weakened over the period, with total assets falling from €99.5K in 2023 to €70.9K in 2024 and €60.6K in 2025. Equity was negative throughout and declined to -€274.3K in 2025, while liabilities increased to €335.1K. Asset turnover reached 3.55x in 2025, and revenue per employee was €107.6K, suggesting a relatively high sales base relative to staff.